Edition:
United States

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

17.77USD
11:38am EDT
Change (% chg)

$-0.15 (-0.84%)
Prev Close
$17.92
Open
$17.82
Day's High
$17.87
Day's Low
$17.46
Volume
51,711
Avg. Vol
658,427
52-wk High
$25.92
52-wk Low
$8.90

Select another date:

Thu, Mar 15 2018

BRIEF-Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals For Infringement Of Korlym Patents

* CORCEPT THERAPEUTICS FILES LAWSUIT AGAINST TEVA PHARMACEUTICALS FOR INFRINGEMENT OF KORLYM PATENTS

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application

* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA

BRIEF-Corcept Therapeutics, Dohmen Entered Into Settlement Agreement And Mutual Release Of Any And All Claims That May Have Existed Between Parties

* CORCEPT THERAPEUTICS - CO, DOHMEN ENTERED INTO SETTLEMENT AGREEMENT AND MUTUAL RELEASE OF ANY AND ALL CLAIMS THAT MAY HAVE EXISTED BETWEEN PARTIES

BRIEF-Corcept Therapeutics posts Q3 earnings per share $0.11

* Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update

Select another date: